Please assess the completion status of the following clinical trial:

Trial Title: Superficial Partial-Thickness Burn Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide informed consent~* 18 years of age or older, male and female~* Patients who have sustained superficial, partial-thickness burn wounds ≤ to 10% of total body surface area (TBSA)~* Patients otherwise in good general physical and mental health, as per the investigator's clinical judgment~Exclusion Criteria:~* Inability to provide informed consent~* Deep partial-thickness burns and full-thickness burns~* Radiation, chemical, or electrical burn injury~* Patients with burns primarily located to the face, genitals, or span across joints~* Patients whose burn injury was ≥ to 48 hours prior to entry into the UPMC Mercy Burn Center Clinic.~* Patients with uncontrolled cerebrovascular disease, cardiovascular disease, endocrine disease, hepatic disease, or renal disease; or other severe conditions for whom, in the physician investigators' discretion, would render study participation unsafe~* Patients with documented or self-reported shellfish allergies~* Current pregnancy~* Patients with concurrent burn related injuries or inhalation injury that would put the patient at increased risk, per physician discretion~* Any condition to which in the investigator's discretion would render study enrollment a safety concern for the patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Silver sulfadiazine (Type: ACTIVE_COMPARATOR): Topical management via dressings provide a barrier against microbial infection. The current gold standard for burn wound dressings is silver (nanoparticulate or ionic), and it has shown some efficacy in treating infections, but it does not demonstrate an ability to prevent infections and some treatment guidelines even recommend against its use. Although silver dressing is preferred for military use, a retrospective review spanning 10 years of use in military environments showed that silver was not more effective than other antimicrobial topical treatments, and a meta-analysis with over 2500 surgical patients found silver sulfadiazine was associated with increased infection rates and hospital length-of-stays were two days longer on average.
- Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser (Type: EXPERIMENTAL): Synedgen has developed Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser. These products are Food and Drug Administration (FDA) 510(k) cleared wound care medical devices, formulated with a novel biocompatible chitosan derivative, poly (acetyl, arginyl) glucosamine. SynePure™ Wound Cleanser is optimized for the cleansing and debridement of wounds and thermal injuries, and Catasyn™ Advanced Technology Hydrogel serves as a protective gel dressing. Together, these products reduce inflammation in wounds, aggregate bacteria and disrupt bacterial biofilms, and accelerate healing.

Based on this trial design, predict the completion outcome and termination type (if applicable).